Gothenburg, January 14, 2022 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immuno-oncological treatments focused on CAR T-cells and oncolytic viruses, announces that the nomination committee has agreed on a proposal for the Annual General Meeting in March 2022.
On April 26 2021, the Annual General Meeting established rules to guide the work of the Nomination Committee. The three largest owners at September 30 were Magnus Essand, Di Yu and Jamal El-Mosleh, controlling 47.1% of the votes, have earlier been appointed as nomination committee. The nomination committee has discussed the work of the Board for the past year and unanimously prepared a proposal for the Meeting. The Elicera Board of Directors was newly elected in autumn 2019 and the representatives for the largest owners are satisfied with the work of the Board and therefore see no reason to change.
The Nomination Committee has thus unanimously proposed a re-election of the current Board: Agneta Edberg (chair), Magnus Essand, Christina Herder, Margareth Jorvid and Jan Zetterberg as ordinary members and Di Yu as deputy member. Karin Hoogendoorn has declined re-election.
The Committee also proposes the re-election of RSM, with signatory auditor Kristoffer Håkansson.
The Nomination Committee does not propose any changes to Board remuneration. Payment of SEK 7,500 per month is proposed for external members and SEK 10,000 per month is proposed for the Chairman of the Board. The auditor will be remunerated according to the approved offer.
The Annual General Meeting will be held on March 7t at 3:00 p.m. at the offices of Advokatfirman Delphi (Mäster Samuelsgatan 17 in Stockholm) and attorney Mats Dahlberg has been proposed to chair the Meeting.
For more information, contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)
Tel: +46 (0) 703 31 90 51
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical stage cell and gene therapy company developing the next generation of immuno-oncological treatments. The company has four drug candidates in development, two CAR T-cells and two oncolytic viruses, based on research carried out by Professor Magnus Essand’s research group at Uppsala University. In addition, Elicera has a fully developed technology platform, iTANK, which can be used to optimize the effect of all CAR T-cell therapies under development and activate killer T-cells against cancer. The Elicera share (ELIC) is listed on the Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: firstname.lastname@example.org, tel: +468-503 000 50.
For more information, please visit www.elicera.se